Exploring the feasibility of an anti‐idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2βanti‐idiotypic antibodies
Exploring the feasibility of an anti‐idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2βanti‐idiotypic antibodies
复制标题
探索抗独特型可卡因疫苗的可行性：分析能够诱导 Ab2β 抗独特型抗体的抗可卡因抗体 (Ab1) 的特异性
作者：
D. Schabacker;K. Kirschbaum;M. Segre
使用与蛋白质载体结合的可卡因分子进行常规疫苗接种是治疗成瘾的新方法。实验表明，这种策略可以改变可卡因挑战的药代动力学以及精神兴奋作用。本研究的目的是调查是否可以成功使用一种更稳定且争议较少的分子，即模仿可卡因分子 (Ab2β) 构型的抗独特型抗体来代替可卡因。两种可卡因结合物将可卡因分子的不同区域呈现给免疫系统，用于生产可卡因特异性单克隆抗体 (Ab1)。然后产生了几种抗独特型抗体。其中四个被鉴定为 Ab2β，即抗原的内部图像；当注射到 BALB/c 小鼠体内时，它们引发了抗可卡因反应。与用无关抗体免疫的对照动物大脑中发现的可卡因水平相比，四种 Ab2β (K1-4c) 之一引起的抗可卡因反应足以显着降低可卡因攻击后针对大脑的可卡因水平。总之，抗独特型疫苗的可能性似乎值得追求。
Conventional vaccination with the cocaine molecule conjugated to a protein carrier is a new approach in the treatment of addiction. Experimentally, this strategy has been shown to alter the pharmacokinetics as well as the psychostimulant effect of a cocaine challenge. The purpose of this study was to investigate whether a more stable and less controversial molecule, an anti‐idiotypic antibody, which mimics the configuration of the cocaine molecule (Ab2β), could be successfully used instead of cocaine. Two cocaine conjugates that presented different areas of the cocaine molecule to the immune system were used to produce monoclonal antibodies specific for cocaine (Ab1). Several anti‐idiotypic antibodies were then produced. Four were identified as Ab2β, or internal images of the antigen; when injected into BALB/c mice, they elicited an anticocaine response. The anticocaine response elicited by one of the four Ab2β (K1–4c) was sufficient to significantly reduce the level of cocaine that targeted the brain following cocaine challenge, compared with the level of cocaine found in the brain of control animals immunized with irrelevant antibody. In conclusion, the possibility of an anti‐idiotypic vaccine seems to be worth pursuing.
登录
查看更多内容
影响因子：
--
作者：
Pulak K. Tripathi;Hongxing Qin;M. Bhattacharya‐Chatterjee;Roberto L. Ceriani;K. Foon;S. Chatterjee
通讯作者：
Pulak K. Tripathi;Hongxing Qin;M. Bhattacharya‐Chatterjee;Roberto L. Ceriani;K. Foon;S. Chatterjee
影响因子：
56.9
作者：
GAWIN, FH
通讯作者：
GAWIN, FH
影响因子：
7.3
作者：
MELTZER, PC;LIANG, AY;MADRAS, BK
通讯作者：
MADRAS, BK
乙型肝炎疫苗开发的新方法。
DOI：
10.1016/0168-1656(95)00117-4
发表时间：
1996
期刊：
Journal of biotechnology.
影响因子：
--
作者：
Thanavala,Y
通讯作者：
Thanavala,Y
影响因子：
56.9
作者：
LANDRY, DW;ZHAO, K;GEORGIADIS, TM
通讯作者：
GEORGIADIS, TM